AT-7519(HCI)/

Solubility:Soluble in DMSO

Storage:-20C 2 years

Biologieal

PHA-848125 is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity.

Reference

Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy By Albanese, Clara; Alzani, Rachele; Amboldi, Nadia; Avanzi, Nilla; Ballinari, Dario; Brasca, Maria Gabriella; Festuccia, Claudio; Fiorentini, Francesco; Locatelli, Giuseppe; Pastori, Wilma; et al From Molecular Cancer Therapeutics (2010), 9(8), 2243-2254.